

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

PHARMACOSMOS A/S,  
Petitioner

v.

LUITPOLD PHARMACEUTICALS, INC.,  
Patent Owner

---

Patent No. 7,754,702

Title: METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON

---

*Inter Partes* Review No. 2015-01490

---

**PETITIONER'S OPPOSITION TO PATENT OWNER'S  
MOTION TO EXCLUDE**

## TABLE OF CONTENTS

|      |   |   |
|------|---|---|
| I.   | RELIEF REQUESTED.....   | 1 |
| II.  | APPLICABLE PRINCIPLES .....   | 1 |
| III. | ARGUMENT.....   | 2 |
|      | A. Patent Owner’s Attempt To Exclude Dr. Manzi’s Testimony (Ex. 1054) Is<br>Untimely And Misleading ..... | 2 |
|      | B. Wang (Exhibit 1055) And Its Supplementary Content (Exhibit 1056) Are<br>Admissible .....               | 3 |
|      | 1. Exhibits 1055 and 1056 Are Relevant .....  | 3 |
|      | 2. Exhibits 1055 and 1056 Are Not Hearsay .....   | 5 |
|      | 3. Statements Citing To Exhibits 1055 and 1056 Should Not Be Excluded ...                                 | 5 |
|      | C. Keating (Exhibit 1057) Is Admissible.....  | 6 |
|      | 1. Exhibit 1057 Is Relevant.....  | 6 |
|      | 2. Exhibit 1057 Is Not Hearsay .....  | 6 |
|      | 3. Statements Citing To Exhibit 1057 Should Not Be Excluded.....  | 7 |
|      | D. The Galenica Group Presentation (Exhibit 1059) Is Admissible.....                                      | 7 |
|      | 1. Exhibit 1059 Is Relevant.....  | 7 |
|      | 2. Exhibit 1059 Is Not Hearsay .....  | 8 |
|      | 3. Exhibit 1059 Is Properly Authenticated.....  | 8 |
|      | 4. Statements Citing To Exhibit 1059 Should Not Be Excluded.....  | 9 |

E. The Charles River Monograph For C57BL/6 Mice (Exhibit 1060) Is Admissible .....9

- 1. Exhibit 1060 Is Relevant.....10
- 2. Exhibit 1060 Is Not Hearsay .....10
- 3. Exhibit 1060 Is Properly Authenticated.....11
- 4. Statements Citing To Exhibit 1060 Should Not Be Excluded.....11

F. The Webpage For The San Diego Zoo (Exhibit 1061) Is Admissible .....12

- 1. Exhibit 1061 Is Relevant.....12
- 2. Exhibit 1061 Is Not Hearsay .....12
- 3. Exhibit 1061 Is Properly Authenticated.....13
- 4. Statements Citing To Exhibit 1061 Should Not Be Excluded.....13

G. Document Regarding Imferon®’s Recall (Exhibit 1063) Is Admissible .....14

- 1. Exhibit 1063 Is Not Hearsay .....14
- 2. Exhibit 1063 Is Properly Authenticated.....14
- 3. Statements Citing To Exhibit 1063 Should Not Be Excluded.....15

IV. CONCLUSION.....15

## I. RELIEF REQUESTED

Petitioner Pharmacosmos A/S (“Petitioner”) timely provides the following opposition to Patent Owner’s Motion to Exclude Evidence (Paper 44; “Motion”), filed on August 9, 2016. Luitpold Pharmaceuticals (“Patent Owner”) seeks to exclude not only Petitioner’s Exhibits 1055, 1056, 1057, 1059, 1060, 1061 and 1063 and portions of Patent Owner’s own expert’s deposition testimony, Exhibit 1054, (the “Challenged Exhibits”), but also Petitioner’s arguments that cite to these exhibits, even if such citation is incidental to the argument. Neither position is tenable. Contrary to Patent Owner’s representations, the Challenged Exhibits are admissible under the Federal Rules of Evidence and the Code of Federal Regulations, and the bulk of Petitioner’s related arguments should be permitted regardless of such admissibility. The Motion should be denied in its entirety.

## II. APPLICABLE PRINCIPLES

Motions to exclude are limited to “challeng[ing] the admissibility of evidence” under the Federal Rules of Evidence (“FRE”) or any Board rules that supersede them, *see* Office Patent Trial Practice Guide, 77 Fed. Reg. 48756, 48767 (Aug. 14, 2012), and as the movant, Patent Owner carries the burden of proof to establish entitlement to having the evidence excluded. *See* 37 C.F.R. § 42.20(c). A motion to exclude evidence also must “explain why the evidence is not admissible (*e.g.*, relevance or hearsay), but may not be used to challenge the sufficiency of the evidence to prove a particular fact.” Office Patent Trial Practice

Guide, 77 Fed. Reg. at 48767.

Moreover, 37 C.F.R. § 42.64(a) requires that an “objection to the admissibility of deposition evidence ... be made during the deposition.” As such, “[a]n objection at the time of examination ... must be noted on the record.” Office Patent Trial Practice Guide, 77 Fed. Reg. at 48772; *see also id.* at 48767.

### III. ARGUMENT

#### A. Patent Owner’s Attempt To Exclude Dr. Manzi’s Testimony (Ex. 1054) Is Untimely And Misleading

Patent Owner seeks to exclude testimony of their own expert, Dr. Manzi, on the issue of the reference, Beshara (Ex. 2041), for alleged “misinterpretation” of that testimony. Patent Owner’s request should be denied for at least the following reasons.

First, it is not timely, as Patent Owner failed to raise any objection to such testimony in Patent Owner’s Objections to Petitioner’s Reply and Opposition Evidence. Objections made during Dr. Manzi’s Deposition, cited as the basis for timeliness in the Motion, were not made to any characterization of the testimony, and therefore the Motion raises a new issue.

Second, Patent Owner, in the Motion, misleadingly contends that Petitioner cited Dr. Manzi as confirming that “data in Beshara actually corresponds to data in the working examples and detailed description of the ‘702 patent.”” Motion at 13. In contrast, Petitioner stated that “Dr. Manzi, Patent Owner’s expert, confirmed

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.